Abstract:Objective: Previous research has shown that ketamine can improve social functions. In addition, evidence also suggests that ketamine can alleviate pain. Herein, we propose that ketamine-induced improvements in pain and depression are partially mediated by a reduction in pain. We aimed to determine whether improvements in pain -mediated changes in psychological function were associated with ketamine treatment.Method: This trial included unipolar or bipolar patients (n = 103) who received 6 intravenous infusions (0.5 mg/ kg) of ketamine over 2 weeks. The severity of current depressive symptoms and social function were evaluated by the Montgomery-angstrom sberg Depression Scale (MADRS), Self-Rating Depression Scale (SDS) and Global Assessment Function (GAF), respectively, at baseline and on day 13 and day 26. At the same time points, the three di-mensions of pain, including the sensory index, affective index and present pain intensity (PPI), were measured by the Simple McGill Pain Scale (SF-MPQ).Results: The mixed model results showed that ketamine plays an important role in improving the psychosocial functioning of patients. There was a significant decrease from baseline to the day 13 and day 26, indicating that the pain index of the patient improved significantly. Mediation analysis showed that for SDS score (coef =-5.171, 95 % CI[-6.317,-4.025]) and GAF score (coef = 1.021, 95 % CI[0.848, 1.194]), the overall effect of ketamine was observable. The overall indirect and direct effects of ketamine on social functioning were signif-icant (SDS: direct: coef =-1949 to-2114; total indirect: from 0.594 to 0.664; GAF: from 0.399 to 0.427; total indirect: coef = 0.593 to 0.664). The MADRS total score and emotional index were important mediators of the association between ketamine treatment and improvements in subjective and objective social functioning. Conclusion: Depressive symptom severity and the affective index of pain partially mediated improvements in social function after six repeated ketamine treatments among patients with bipolar or unipolar depressive disorder.

Sex differences in the effects of repeated ketamine infusions on bone markers in patients with unipolar and bipolar depression

Gender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users

Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum BDNF levels: a post-hoc analysis

Effect of esketamine on serum neurotransmitters in patients with postpartum depression: a randomized controlled trial

Beneficial effects of arketamine on the reduced bone mineral density in susceptible mice after chronic social defeat stress: Role of the gut–microbiota–bone–brain axis

Ketamine May Exert Rapid Antidepressant Effects Through Modulation of Neuroplasticity, Autophagy, and Ferroptosis in the Habenular Nucleus.

Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients

Effects of a single subanesthetic dose of esketamine on postoperative subthreshold depressive symptoms in patients undergoing unilateral modified radical mastectomy: a randomised, controlled, double-blind trial

Functional Connectivity of the Amygdala and the Antidepressant and Antisuicidal Effects of Repeated Ketamine Infusions in Major Depressive Disorder

Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation

Short-term Cognitive Effects of Repeated-Dose Esketamine in Adolescents with Major Depressive Disorder and Suicidal Ideation: a Randomized Controlled Trial.

Investigation of Medical Effect of Multiple Ketamine Infusions on Patients with Major Depressive Disorder

A meta-analysis of the effects of ketamine on suicidal ideation in depression patients

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential

Effect of Antidepressants on Bone Mineral Density and Bone Metabolism in Ovariectomized Depressed Rats

Ketamine reverses chronic corticosterone-induced behavioral deficits and hippocampal synaptic dysfunction by regulating eIF4E/BDNF signaling

Pain mediates the improvement of social functions of repeated intravenous ketamine in patients with unipolar and bipolar depression

Ketamine exerts a protective role in a cell-based model of major depressive disorder via the inhibition of apoptosis and inflammation and activation of the Krebs cycle

Effects of ketamine on metabolic parameters in depressive disorders: A systematic review

Sigma-1 receptor activation mediates the sustained antidepressant effect of ketamine in mice via increasing BDNF levels

Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans